Advising Eli Lilly on Ukrainian legal aspects, including corporate, employment and cross-border tax structuring matters, related to the worldwide acquisition by Eli Lilly of the Novartis animal health unit for US$ 5.4 billion and its integration with Eli Lilly’s animal health unit (Elanco).

Marchenko Danevych developed legal mechanism and scheme of transferring and integration of Elanco employees into Eli Lilly structure, including drafting of range of documents requested for realization of transaction process.

As a result of this acquisition Elanco, based in Greenfield, Indiana, shall become the world’s second largest animal health company.

This was the second largest acquisition by Eli Lilly following its acquisition of ImClone Systems for US$ 6.5 billion in 2008.


USUBC note: Eli Lilly is a members of USUBC.